息肉状脉络膜血管病变两种血管造影亚型玻璃体内注射雷珠单抗12个月疗效的比较。
Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
作者信息
Nakai Shunichiro, Honda Shigeru, Miki Akiko, Matsumiya Wataru, Nakamura Makoto
机构信息
Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
出版信息
Ophthalmologica. 2017;237(3):123-127. doi: 10.1159/000455273. Epub 2017 Mar 22.
BACKGROUND
To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV).
METHODS
This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR.
RESULTS
The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 ± 1.7 in type 1 PCV and 1.2 ± 1.3 in type 2 PCV.
CONCLUSIONS
The outcomes of IVR may be different between two angiographic subtypes of PCV.
背景
比较息肉状脉络膜血管病变（PCV）两种血管造影亚型玻璃体内注射雷珠单抗（IVR）的12个月疗效。
方法
这是一项对38例初治PCV病例的回顾性队列研究。连续进行3次IVR，并根据需要进行再次治疗。随后，根据分支血管网状态将PCV病例分为两种表型（1型18例，2型20例）。在初次IVR后长达12个月的时间里，对每种PCV亚型的最佳矫正视力（BCVA）进行评估。
结果
1型PCV的平均BCVA较基线有显著改善，而2型PCV则没有。在2型PCV中，3例在初次IVR后6个月出现严重视力丧失。1型PCV的平均再次治疗次数为1.9±1.7次，2型PCV为1.2±1.3次。
结论
PCV的两种血管造影亚型接受IVR治疗的疗效可能不同。
Zotero 插件